Related Experiment Video
Updated: Aug 14, 2026
12:45
Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
The problem of non-response to cardiac resynchronization therapy
David H Birnie1, Anthony Sl Tang
1University of Ottawa Heart Institute, Ottawa, Ontario, Canada. dbirnie@ottawaheart.ca
Current Opinion in Cardiology
|December 16, 2005
Summary
Cardiac resynchronization therapy (CRT) benefits advanced heart failure patients, but up to 50% may not respond. Research is investigating factors like mechanical dyssynchrony to improve CRT effectiveness and patient outcomes.
Area of Science:
- Cardiology
- Medical Devices
- Heart Failure Management
Background:
- Cardiac resynchronization therapy (CRT) is a key treatment for advanced heart failure (HF) patients with intraventricular conduction delay.
- While CRT improves quality of life and reduces HF hospitalizations, a significant portion of patients do not respond or achieve suboptimal benefits.
Purpose of the Study:
- To review the frequency of non-response to CRT in eligible heart failure patients.
- To discuss the multifactorial reasons for CRT non-response.
- To explore potential solutions and ongoing research to enhance CRT efficacy.
Main Methods:
- Critical analysis of existing clinical data on CRT response rates.
- Review of studies investigating factors contributing to CRT non-response.
- Examination of emerging techniques for patient selection and therapy optimization.
Main Results:
- Non-response rates to CRT are higher than commonly cited, potentially affecting 40-50% of patients.
- Key factors influencing non-response include the degree of mechanical dyssynchrony, left ventricular pacing site, and the underlying cause of HF.
- Research is actively exploring methods to quantify mechanical dyssynchrony and optimize LV lead placement.
Conclusions:
- CRT remains a significant advancement in treating advanced HF.
- Addressing the substantial rate of CRT non-response is crucial for improving patient outcomes.
- Ongoing research focuses on personalized approaches to maximize CRT benefits.
Related Concept Videos
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:30Cardiac Action Potential
Cardiac action potentials are essential for proper heart function, enabling the rhythmic contractions needed for adequate blood circulation. Nodal cells and Purkinje fibers, specialized for electrical conduction, generate these action potentials.
The cardiac action potential process involves a series of phases characterized by the movement of ions across the cardiac cell membranes, leading to the depolarization and repolarization of the cardiac myocytes.
Ionic Basis of Cardiac Action Potentials
The cardiac action potential process involves a series of phases characterized by the movement of ions across the cardiac cell membranes, leading to the depolarization and repolarization of the cardiac myocytes.
Ionic Basis of Cardiac Action Potentials